DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1579)

Osteoarthritic Pain | Current Treatment | Detailed, Expanded Analysis (US)

Osteoarthritic Pain | Current Treatment | Detailed, Expanded Analysis (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Market Outlook
Osteoarthritis ( OA ) pain is an extremely prevalent type of chronic pain, affecting more than 30 million individuals in the United States, and is the second-largest segment of the overall chronic pain market. Treatment of OA pain is dominated by cost-effective generic treatments, in addition to costly abuse-deterrent reformulations of opioid analgesics and new combinations of existing analgesics that attempt to mitigate side effects; no truly novel or mechanism-based therapies are currently available. The key drug classes prescribed to treat OA pain, nonsteroidal anti-inflammatory drugs ( NSAID s) and opioid analgesics, are associated with a host of side effects including gastrointestinal, cardiovascular, and/or abuse risks. As such, treatment of this indication can be challenging for physicians because existing therapies are frequently inadequate in achieving long-term analgesia in many patients.
Questions Answered

How is OA pain being treated in the United States today, and what are the drivers and constraints influencing physicians’ treatment decisions?
What impact have the recent launches of new analgesics such as Iroko’s Vivlodex and Purdue’s Hysingla ER had on physician prescribing behavior for OA pain?
What factors drive switching between or discontinuation of select analgesics (, Depomed’s Nucynta ER , Horizon’s Vimovo, Pfizer’s Embeda)?
How does patient risk for abuse/history of abuse influence physicians’ prescribing of opioid analgesics for OA pain?

Product Description
Current Treatment: Physician Insights provides physician insights on treatment paths, prescribing behaviors, and the factors and perceptions driving brand usage so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.

  • Pub Date: November 2017
  • Author(s): Bethany A. Kiernan, PhD; Andrea Witt, PhD; Joyce Spadafora, ALM

Request report

Related reports:
You may also be interested in: